Related Experiment Videos
Hyperprolactinemia: etiology, diagnosis, and management.
Peak Mann Mah1, Jonathan Webster
1Endocrine Centre, Northern General Hospital, Sheffield, United Kingdom.
Seminars in Reproductive Medicine
|January 22, 2003
Summary
Hyperprolactinemia, often caused by prolactinomas, is a common pituitary disorder. Dopamine agonists like cabergoline and bromocriptine are primary treatments, with bromocriptine preferred for conception.
Area of Science:
- Endocrinology
- Neuroendocrinology
- Pituitary Disorders
Background:
- Hyperprolactinemia is the most frequent endocrine dysfunction of the hypothalamic-pituitary axis.
- Prolactinomas are the leading cause of chronic hyperprolactinemia after excluding pregnancy, hypothyroidism, and drug-induced causes.
- Symptoms include hypogonadism, infertility, galactorrhea, osteopenia, and mass effects.
Purpose of the Study:
- To outline the diagnostic approach to hyperprolactinemia.
- To discuss treatment goals and options for hyperprolactinemia.
- To compare dopamine agonist efficacy and safety profiles.
Main Methods:
- Clinical evaluation including history and physical examination.
- Laboratory testing to confirm hyperprolactinemia.
- Diagnostic imaging (sella turcica) to identify the cause.
Main Results:
- Dopamine agonists are the first-line treatment for most hyperprolactinemia cases.
- Cabergoline demonstrates higher efficacy and better tolerability than bromocriptine.
- Bromocriptine is recommended for pregnant or conception-seeking patients due to established safety data.
Conclusions:
- Treatment aims to normalize prolactin levels, restore gonadal function, and mitigate long-term effects.
- Transsphenoidal surgery is reserved for specific cases of resistance or intolerance to dopamine agonists.
- Pharmacological management with dopamine agonists is highly effective for hyperprolactinemia.